Nabsys and LUMC Advance FSHD Research With Genome Mapping
PROVIDENCE, R.I., June 15, 2026 Nabsys 2.0, LLC has announced a strategic research collaboration with Leiden University Medical Center...
Bone Health
Advertisement
Neurocrine’s CRENESSITY Delivers Two-Year Cardiometabolic Benefits in Adult CAH
SAN DIEGO, June 15, 2026 Neurocrine Biosciences has unveiled new two-year data from its Phase 3 CAHtalyst® Adult study,...
AstraZeneca Reports Positive Phase III Results for Eneboparatide in HypoPT
PRAGUE, Czech Republic, May 12, 2026 AstraZeneca and Alexion announced positive Phase III clinical trial results for eneboparatide (AZP-3601),...
Apotex Wins Approval for DENOZA Biosimilar in Canada
TORONTO, Ontario, Canada, April 7, 2026 Apotex Inc., a leading global pharmaceutical company, announced that Health Canada has approved...
FDA Approves Accord BioPharma’s Denosumab Biosimilars, Expanding Access to Bone-Health Therapy
Durham, North Carolina, November 2025 Accord BioPharma has announced FDA approval of two denosumab biosimilars, OSVYRTI (denosumab-desu) and JUBEREQ...
Advertisements
Biocon Biologics Wins FDA Nod for Denosumab Biosimilars
BENGALURU, India & BRIDGEWATER, N.J. – September 17, 2025 –Biocon Biologics Ltd. (BBL), a global leader in biosimilars and...
Natural Vitamin D3 Supplement Supports Year-Round Sufficiency
FORT LAUDERDALE, September 3, 2025 – As daylight dwindles in parts of the northern hemisphere, maintaining adequate vitamin D...
Advertisement
